{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Entresto&page=2", "query": { "intervention": "Entresto", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Entresto&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-08T01:50:36.366Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03508739", "title": "Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2", "Pre-diabetic", "Hypertension", "Elevated Blood Pressure" ], "interventions": [ { "name": "Sacubitril/Valsartan 200mg (blinded)", "type": "DRUG" }, { "name": "Valsartan 160mg (blinded)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 25, "start_date": "2018-06-01", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-09-08T01:50:36.366Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03508739" }, { "nct_id": "NCT03506412", "title": "Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Heart Failure With Preserved Ejection Fraction" ], "interventions": [ { "name": "Entresto™ 49Mg-51 mg tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 40, "start_date": "2018-06-25", "completion_date": "2021-03-23", "has_results": true, "last_update_posted_date": "2022-02-04", "last_synced_at": "2026-09-08T01:50:36.366Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03506412" }, { "nct_id": "NCT01692301", "title": "Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "LCZ696", "type": "DRUG" }, { "name": "Olmesartan", "type": "DRUG" }, { "name": "LCZ696 matching placebo", "type": "DRUG" }, { "name": "Olmesartan matching placebo", "type": "DRUG" }, { "name": "amlodipine", "type": "DRUG" }, { "name": "hydrochlorothiazide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 454, "start_date": "2012-12", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-05-04", "last_synced_at": "2026-09-08T01:50:36.366Z", "location_count": 11, "location_summary": "Clearwater, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more", "locations": [ { "city": "Clearwater", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Belzoni", "state": "Mississippi" }, { "city": "Jackson", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT01692301" }, { "nct_id": "NCT00887588", "title": "LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Heart Failure" ], "interventions": [ { "name": "LCZ696", "type": "DRUG" }, { "name": "Valsartan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 307, "start_date": "2009-11", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2015-08-25", "last_synced_at": "2026-09-08T01:50:36.366Z", "location_count": 11, "location_summary": "Little Rock, Arkansas • Chicago, Illinois • Detroit, Michigan + 8 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Grand Island", "state": "Nebraska" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00887588" }, { "nct_id": "NCT02970669", "title": "Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Heart Failure, Reduced Ejection Fraction" ], "interventions": [ { "name": "sacubitril/valsartan (LCZ696)", "type": "DRUG" }, { "name": "enalapril", "type": "DRUG" }, { "name": "matching placebo sacubitril/valsartan (LCZ696)", "type": "DRUG" }, { "name": "matching placebo enalapril", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 140, "start_date": "2016-12-16", "completion_date": "2018-03-19", "has_results": true, "last_update_posted_date": "2021-10-07", "last_synced_at": "2026-09-08T01:50:36.366Z", "location_count": 23, "location_summary": "Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more", "locations": [ { "city": "Fort Payne", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Stockton", "state": "California" }, { "city": "West Hills", "state": "California" }, { "city": "Doral", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02970669" }, { "nct_id": "NCT04649229", "title": "Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "LCZ 696", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Para-aminohippurate", "type": "DRUG" }, { "name": "Iohexol", "type": "DRUG" }, { "name": "Aprepitant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2021-05-27", "completion_date": "2025-05-22", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-09-08T01:50:36.366Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04649229" }, { "nct_id": "NCT05194111", "title": "Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Heart Failure", "Heart Dysfunction" ], "interventions": [ { "name": "Sacubitril-valsartan", "type": "DRUG" }, { "name": "Valsartan", "type": "DRUG" }, { "name": "Carvedilol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 70, "start_date": "2022-08-11", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-09-08T01:50:36.366Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05194111" }, { "nct_id": "NCT02226120", "title": "Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Heart Failure With Reduced Ejection Fraction" ], "interventions": [ { "name": "LCZ696", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1980, "start_date": "2014-10-16", "completion_date": "2017-12-28", "has_results": true, "last_update_posted_date": "2019-02-20", "last_synced_at": "2026-09-08T01:50:36.366Z", "location_count": 24, "location_summary": "Huntsville, Alabama • Muscle Shoals, Alabama • Little Rock, Arkansas + 20 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Oceanside", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02226120" }, { "nct_id": "NCT00549770", "title": "Efficacy and Safety of LCZ696A in Patients With Essential Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "LCZ696", "type": "DRUG" }, { "name": "Valsartan", "type": "DRUG" }, { "name": "AHU377", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1334, "start_date": "2007-09", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2015-08-25", "last_synced_at": "2026-09-08T01:50:36.366Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Buena Park", "state": "California" }, { "city": "Fair Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00549770" }, { "nct_id": "NCT04055428", "title": "NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus", "Cardiovascular Diseases", "Insulin Sensitivity/Resistance", "Metabolic Disease", "Natriuretic Peptides", "Metabolism", "Energy Expenditure" ], "interventions": [ { "name": "Sacubitril, Valsartan 97-103 mg Oral Tablet", "type": "DRUG" }, { "name": "Valsartan 160 mg", "type": "DRUG" }, { "name": "Intravenous Glucose Tolerance Test", "type": "OTHER" }, { "name": "Standardized Meals", "type": "DIETARY_SUPPLEMENT" }, { "name": "Exercise capacity VO2 maximum determination", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "DIETARY_SUPPLEMENT" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2020-08-15", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-09-08T01:50:36.366Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04055428" } ] }